NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
about
Development of targeted therapies in treatment of glioblastomaMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateAdvanced magnetic resonance imaging of the physical processes in human glioblastoma.CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewSuppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.Targeted therapy in gliomas.Erlotinib: early clinical development in brain cancer.Molecularly targeted therapies for recurrent glioblastoma: current and future targets.Incorporation of biomarkers in phase II studies of recurrent glioblastoma.Recent advances in targeted therapy for glioblastoma.Glioblastoma targeted therapy: updated approaches from recent biological insights.Irinotecan-based regimens for recurrent glioblastoma multiforme: [corrected] a systematic review.Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.Investigational new drugs for brain cancer.Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?Contemporary management of high-grade gliomas.Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors.The diagnostic role and clinical relevance of determination of BRAF status in brain tumors.
P2860
Q26778787-85267EA9-3010-4EA4-BBE4-5436F90599C5Q26822717-D63258A8-8F11-46DF-936E-63BEB68FFDCAQ30847284-01FA693E-D459-4D79-B6A7-7F9FCE8B68C7Q34437996-1F8B10DE-BCDF-422E-B6F7-495F463E0897Q35023711-A0498DB8-FCCD-47C9-B9DA-ECE543D06B4AQ35895174-44D35352-360B-4203-B175-270F2883A724Q36270115-6003DFB1-34DD-4C72-90CF-648379C88D13Q36560547-03A09633-A5CC-4C48-AA8B-36AD1D046A17Q38186656-17748D2E-C74D-450D-80B8-C1AE6EBA4DD2Q38212394-3D1DACD6-E722-4E1B-A11D-32F28C5F3450Q38272728-F31360D0-4615-46DE-B63E-8152E7706702Q38298124-336F8409-0E50-4870-A1B9-B5148189B869Q38539386-1CC54E37-D690-4046-B993-816E2F4AA2FBQ38597700-73A44005-23D6-42E1-A049-B0CDBBEE81F9Q38607859-035D3156-6D34-4632-9620-70F2682A260AQ38786782-966FB864-7A5C-4245-9E4F-7B7FB2D3D6A4Q38832510-26118DAA-DDD8-42AF-BF08-9A4BFA4082C4Q39472878-EFBC6531-B5DF-4630-8CD7-064F6D923C37Q42368133-F622D010-1708-494C-8AEF-0A9B6648054FQ47781482-EFB08C49-C23C-4BC1-A78F-F05696D8D88EQ49501093-560EF129-1CC0-470C-A024-F3A051B918F8Q49909297-1E9481DD-1D01-4125-9B3C-C87C39E57981Q52593655-E4A3464F-407D-43B4-9311-0431A75B78C1Q55461604-ACEDF794-827C-4551-A714-764283D9C005
P2860
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
NABTT 0502: a phase II and pha ...... rrent glioblastoma multiforme.
@ast
NABTT 0502: a phase II and pha ...... rrent glioblastoma multiforme.
@en
type
label
NABTT 0502: a phase II and pha ...... rrent glioblastoma multiforme.
@ast
NABTT 0502: a phase II and pha ...... rrent glioblastoma multiforme.
@en
prefLabel
NABTT 0502: a phase II and pha ...... rrent glioblastoma multiforme.
@ast
NABTT 0502: a phase II and pha ...... rrent glioblastoma multiforme.
@en
P2093
P2860
P356
P1433
P1476
NABTT 0502: a phase II and pha ...... urrent glioblastoma multiforme
@en
P2093
David M Peereboom
Jeffrey G Supko
Manmeet S Ahluwalia
New Approaches to Brain Tumor Therapy Consortium
Sarah L Hilderbrand
Stuart A Grossman
Surasak Phuphanich
Tom Mikkelsen
P2860
P304
P356
10.1093/NEUONC/NOS322
P577
2013-01-17T00:00:00Z